Literature DB >> 12536287

Serum uric acid and multiple sclerosis.

S Sotgiu1, M Pugliatti, A Sanna, A Sotgiu, M L Fois, G Arru, G Rosati.   

Abstract

Several studies indicate that patients with multiple sclerosis (MS) have low serum levels of the endogenous antioxidant uric acid (UA), although it has not been established whether UA is primarily deficient or secondarily reduced due to its peroxynitrite scavenging activity. We measured serum urate levels in 124 MS patients and 124 age- and sex-matched controls with other neurological diseases. In addition, we compared UA levels when MS patients were stratified according to disease activity (by means of clinical examination and MRI), duration, disability and course. MS patients had significantly lower serum urate levels than controls (p= 0.001). However, UA levels did not significantly correlate with disease activity, duration, disability or course. Our study favors the view that reduced UA in MS is a primary, constitutive loss of protection against oxidative agents, which deserves further pathogenetic elucidation aimed at future therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12536287     DOI: 10.1007/s100720200059

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  22 in total

1.  No evidence of increased oxidative degradation of urate to allantoin in the CSF and serum of patients with multiple sclerosis.

Authors:  Stefan Kastenbauer; Bernd C Kieseier; Bernhard F Becker
Journal:  J Neurol       Date:  2005-02-23       Impact factor: 4.849

2.  Serum uric acid concentrations are directly associated with the presence of benign multiple sclerosis.

Authors:  Esteban Simental-Mendía; Luis E Simental-Mendía; Fernando Guerrero-Romero
Journal:  Neurol Sci       Date:  2017-06-28       Impact factor: 3.307

3.  Effect of Gender, Age, Diet and Smoking Status on the Circadian Rhythm of Serum Uric Acid of Healthy Indians of Different Age Groups.

Authors:  Ranjana Singh; Pramod Kumar; Devendra Nath Mishra; Ashok Kumar Singh; Raj Kumar Singh; Abbas Ali Mahdi; Cathy Lee Gierke; Germaine Cornelissen
Journal:  Indian J Clin Biochem       Date:  2017-12-21

4.  Serum uric acid levels in multiple sclerosis patients inversely correlate with disability.

Authors:  A L Guerrero; F Gutiérrez; F Iglesias; J Martín-Polo; S Merino; J I Martín-Serradilla; E Laherrán; M A Tejero
Journal:  Neurol Sci       Date:  2011-02-16       Impact factor: 3.307

5.  Novel allelic variants and evidence for a prevalent mutation in URAT1 causing renal hypouricemia: biochemical, genetics and functional analysis.

Authors:  Blanka Stiburkova; Ivan Sebesta; Kimiyoshi Ichida; Makiko Nakamura; Helena Hulkova; Vladimir Krylov; Lenka Kryspinova; Helena Jahnova
Journal:  Eur J Hum Genet       Date:  2013-02-06       Impact factor: 4.246

6.  Serum uric acid levels and neuromyelitis optica.

Authors:  Fuhua Peng; Xiufeng Zhong; Xuhui Deng; Wei Qiu; Aimin Wu; Youming Long; Xueqiang Hu; Qing Li; Ying Jiang; Yongqiang Dai
Journal:  J Neurol       Date:  2010-01-22       Impact factor: 4.849

7.  Association of serum bilirubin and uric acid levels changes during neuroinflammation in patients with initial and relapsed demyelination attacks.

Authors:  Srdjan Ljubisavljevic; Ivana Stojanovic; Slobodan Vojinovic; Maja Milojkovic; Olivera Dunjic; Dragan Stojanov; Dusica Pavlovic
Journal:  Metab Brain Dis       Date:  2013-04-23       Impact factor: 3.584

Review 8.  Rare copresent rheumatoid arthritis and gout: comparison with pure rheumatoid arthritis and a literature review.

Authors:  Chang-Fu Kuo; Wen-Pin Tsai; Lieh-Bang Liou
Journal:  Clin Rheumatol       Date:  2007-12-07       Impact factor: 2.980

9.  Oral administration of inosine promotes recovery after experimental spinal cord injury in rat.

Authors:  Maria Kuricova; Valent Ledecky; Tomas Liptak; Aladar Madari; Ivana Grulova; Lucia Slovinska; Miriam Nagyova; Dasa Cizkova
Journal:  Neurol Sci       Date:  2014-06-10       Impact factor: 3.307

10.  Plasma urate and risk of Parkinson's disease.

Authors:  M G Weisskopf; E O'Reilly; H Chen; M A Schwarzschild; A Ascherio
Journal:  Am J Epidemiol       Date:  2007-06-20       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.